论文部分内容阅读
宫内膜腺癌扩展至宫颈,无论是肉眼还是潜在的病变对存活率均不利.据报导总五年存活率为40～60%,明显低于Ⅰ期病人存活率(70～90%),部份是由于Ⅱ期病人有较高的盆腔淋巴转移率(Morrow等复习文献发现Ⅱ期病人有36.5%,Ⅰ期病人仅10.6%).但Ⅱ期病人多因年龄、肥胖及其他手术禁忌未能精确进行外科分期.多数作者对Ⅱ期病人使用术前镭疗或全盆外放射.1968～1976年,挪威镭疗医院(NRH)将所有Ⅱ期内膜癌病人作随机临床试验,目的是:①评价预后因素;②研究盆腔外放射的价值.共174例
Endometrial adenocarcinoma extended to the cervix, both macroscopical and potential lesions on the survival rate are adverse.It was reported that the overall five-year survival rate was 40 to 60%, significantly lower than the survival rate of stage Ⅰ patients (70 to 90%), Partly because of higher rates of pelvic lymphatic metastasis in stage II patients (reviewed by Morrow et al found 36.5% of stage II patients and 10.6% of stage I patients), but stage II patients were often taboo because of age, obesity and other surgeries Can be accurately surgical staging.Most of the authors of patients with stage Ⅱ preoperative radiotherapy or pelvic radiation .1968 ~ 1976, Norwegian radiotherapy hospital (NRH) will be all Ⅱ endometrial cancer patients for randomized clinical trials, the purpose is : ① evaluation of prognostic factors; ② study of the value of extra-pelvic radiation. A total of 174 cases